Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03261947
Recruitment Status : Recruiting
First Posted : August 25, 2017
Last Update Posted : September 24, 2019
Sponsor:
Information provided by (Responsible Party):
Takeda ( Millennium Pharmaceuticals, Inc. )

Tracking Information
First Submitted Date  ICMJE August 23, 2017
First Posted Date  ICMJE August 25, 2017
Last Update Posted Date September 24, 2019
Actual Study Start Date  ICMJE October 25, 2017
Estimated Primary Completion Date November 19, 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: July 17, 2018)
  • Percentage of Participants with Dose Limiting Toxicities (DLTs) in Western Safety Cohort [ Time Frame: Baseline up to 1 year ]
    DLT includes: Non-febrile Grade 4 neutropenia, Febrile neutropenia: Grade greater than or equal to (>=) 3 neutropenia, Grade 4 thrombocytopenia, grade >=3 thrombocytopenia of any duration accompanied by grade 2 bleeding or requiring transfusion, delay in the initiation of cycle 2 by more than 14 days due to a lack of adequate recovery of treatment-related hematological or nonhematologic toxicities, grade 2 ejection fraction decreased by echocardiogram (ECHO) or multiple gated acquisition (MUGA) scan, Grade 4 laboratory abnormalities, other grade 2 nonhematologic toxicities that are considered by the investigator to be related to study drug and dose-limiting, participants receiving less than (<) 50 percent (%) of doses (<7 doses) of the planned TAK-931 dosing in cycle 1 due to study drug-related adverse events (AEs), grade >=3 nonhematologic toxicity with the few exceptions: Grade 3 arthralgia/ myalgia, fatigue, laboratory abnormalities, nausea and/or emesis or diarrhea.
  • Percentage of Participants with Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), TEAEs Leading to Dose Modifications and TEAEs Leading to Treatment Discontinuation in Western Safety Cohort [ Time Frame: Baseline up to 1 year ]
    An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. A SAE is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria.
  • Disease Control Rate (DCR) [ Time Frame: Baseline up to 1 year ]
    DCR is defined as percentage of participants with complete response (CR), partial response (PR) plus stable disease (SD) >=6 weeks from treatment initiation. Response and progression is evaluated in this study using the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST V 1.1) for lesions: CR is defined as disappearance of all lesions. PR is defined as at least a 30% decrease in the sum of the longest diameter (LD) of lesions, taking as reference the baseline sum LD. Progressive disease (PD) is defined as at least a 20% increase in the sum of the LD of lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions Stable disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started.
Original Primary Outcome Measures  ICMJE
 (submitted: August 23, 2017)
  • Percentage of Participants with Dose Limiting Toxicities (DLTs) in Western Safety Cohort [ Time Frame: Baseline up to 1 year ]
    DLT includes: Non-febrile Grade 4 neutropenia, Febrile neutropenia: Grade ≥3 neutropenia, Grade 4 thrombocytopenia, grade ≥3 thrombocytopenia of any duration accompanied by grade 2 bleeding or requiring transfusion, delay in the initiation of cycle 2 by more than 14 days due to a lack of adequate recovery of treatment-related hematological or nonhematologic toxicities, grade 2 ejection fraction decreased by echocardiogram (ECHO) or multiple gated acquisition (MUGA) scan, Grade 4 laboratory abnormalities, other grade 2 nonhematologic toxicities that are considered by the investigator to be related to study drug and dose-limiting, participants receiving <50% of doses (<7 doses) of the planned TAK-931 dosing in cycle 1 due to study drug-related AEs, grade ≥3 nonhematologic toxicity with the few exceptions: Grade 3 arthralgia/ myalgia, fatigue, laboratory abnormalities, nausea and/or emesis or diarrhea.
  • Percentage of Participants with Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), TEAEs Leading to Dose Modifications and TEAEs Leading to Treatment Discontinuation in Western Safety Cohort [ Time Frame: Baseline up to 1 year ]
    An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. A SAE is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria.
  • Disease Control Rate (DCR) [ Time Frame: Baseline up to 1 year ]
    DCR is defined as percentage of participants with complete response (CR), partial response (PR) plus stable disease (SD) ≥6 weeks from treatment initiation. Response and progression is evaluated in this study using the Response Evaluation Criteria in Solid Tumors (RECIST) V 1.1 for lesions: CR is defined as disappearance of all lesions. PR is defined as at least a 30% decrease in the sum of the longest diameter (LD) of lesions, taking as reference the baseline sum LD. Progressive disease (PD) is defined as at least a 20% increase in the sum of the LD of lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions Stable disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started.
Change History Complete list of historical versions of study NCT03261947 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: July 17, 2018)
  • Cmax: Maximum Observed Plasma Concentration for TAK-931 [ Time Frame: Cycle 1 Days 1 and 8 pre-dose and at multiple timepoints (up to 24 hours) post-dose ]
  • Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-931 [ Time Frame: Cycle 1 Days 1 and 8 pre-dose and at multiple timepoints (up to 24 hours) post-dose ]
  • AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Postdose for TAK-931 [ Time Frame: Cycle 1 Days 1 and 8 pre-dose and at multiple timepoints (up to 24 hours) post-dose ]
  • AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-931 [ Time Frame: Cycle 1 Days 1 and 8 pre-dose and at multiple timepoints (up to 24 hours) post-dose ]
  • CLr: Renal Clearance of TAK-931 [ Time Frame: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 24 hours) post-dose ]
    CLr is a measure of apparent clearance of the drug from the urine. The clearance is the rate at which waste substances are cleared from the blood.
  • t1/2z: Terminal disposition phase half-life [ Time Frame: Cycle 1 Day 8 pre-dose and at multiple timepoints (up to 24 hours) post-dose ]
  • CLss/F: Steady-state Apparent Oral Clearance [ Time Frame: Cycle 1 Day 8 pre-dose and at multiple timepoints (up to 24 hours) post-dose ]
    CL/F is apparent clearance of the drug from the plasma, calculated as the drug dose divided by AUC expressed in liters/hour (L/hr).
  • Rac(AUC): Accumulation Ratio Based on AUC Over the Dosing Interval (AUCτ) [ Time Frame: Cycle 1 Day 8 pre-dose and at multiple timepoints (up to 24 hours) post-dose ]
  • Overall Response Rate (CR and PR) [ Time Frame: Baseline up to 1 year ]
    Overall Response rate is defined as the sum of percentage of participants with complete response rate and partial response rate. Response and progression was evaluated in this study Per RECIST V1.1 where CR is defined as disappearance of all lesions, PR is defined as at least a 30% decrease in the sum of the LD of lesions, taking as reference the baseline sum LD. PD is defined as at least a 20% increase in the sum of the LD of lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
  • Duration of Response (DOR) [ Time Frame: Baseline up to 1 year ]
    DOR is defined as the time from the date of first documentation of a CR or PR to the date of first documentation of tumor progression. Per RECIST V1.1, CR is defined as disappearance of all lesions, PR is defined as at least a 30% decrease in the sum of the LD of lesions, taking as reference the baseline sum LD. PD is defined as at least a 20% increase in the sum of the LD of lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
  • Progression Free Survival (PFS) [ Time Frame: From randomization until disease progression or death whichever occurs first (up to 1 year) ]
    PFS is defined as time from start of study treatment to first documentation of disease progression or death due to any cause, whichever occurs first Per RECIST V1.1, PD is defined as at least a 20% increase in the sum of the LD of lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
  • Overall Survival (OS) [ Time Frame: Baseline up to 1 year ]
    OS is the time from start of study treatment to date of death due to any cause.
  • Percentage of Participants with TEAEs in the Tumor-Specific Cohorts [ Time Frame: Baseline up to 1 year ]
    Percentage of participants with Grade >=3 TEAEs, SAEs, TEAEs leading to treatment discontinuation or dose modifications, and clinically significant changes in laboratory values and vital sign measurements in the tumor-specific cohorts will be reported. An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. A SAE is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria.
Original Secondary Outcome Measures  ICMJE
 (submitted: August 23, 2017)
  • Cmax: Maximum Observed Plasma Concentration for TAK-931 [ Time Frame: Days 1 and 8 pre-dose and at multiple timepoints (up to 24 hours) post-dose ]
  • Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-931 [ Time Frame: Days 1 and 8 pre-dose and at multiple timepoints (up to 24 hours) post-dose ]
  • AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Postdose for TAK-931 [ Time Frame: Days 1 and 8 pre-dose and at multiple timepoints (up to 24 hours) post-dose ]
  • AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-931 [ Time Frame: Days 1 and 8 pre-dose and at multiple timepoints (up to 24 hours) post-dose ]
  • CLr: Renal Clearance of TAK-931 [ Time Frame: Day 1 pre-dose and at multiple timepoints (up to 24 hours) post-dose ]
    CLr is a measure of apparent clearance of the drug from the urine. The clearance is the rate at which waste substances are cleared from the blood.
  • t1/2z: Terminal disposition phase half-life [ Time Frame: Day 8 pre-dose and at multiple timepoints (up to 24 hours) post-dose ]
  • CLss/F: Steady-state Apparent Oral Clearance [ Time Frame: Day 8 pre-dose and at multiple timepoints (up to 24 hours) post-dose ]
    CL/F is apparent clearance of the drug from the plasma, calculated as the drug dose divided by AUC expressed in liters/hour (L/hr).
  • Rac(AUC): Accumulation Ratio Based on AUC Over the Dosing Interval (AUCτ) [ Time Frame: Day 8 pre-dose and at multiple timepoints (up to 24 hours) post-dose ]
  • Overall Response Rate (Complete Response [CR] and Partial response [PR]) [ Time Frame: Baseline up to 1 year ]
    Overall Response rate is defined as the sum of percentage of participants with complete response rate and partial response rate. Response and progression was evaluated in this study Per RECIST V1.1 where CR is defined as disappearance of all lesions, PR is defined as at least a 30% decrease in the sum of the LD of lesions, taking as reference the baseline sum LD. PD is defined as at least a 20% increase in the sum of the LD of lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
  • Duration of Response (DOR) [ Time Frame: Baseline up to 1 year ]
    DOR is defined as the time from the date of first documentation of a CR or PR to the date of first documentation of tumor progression. Per RECIST V1.1, CR is defined as disappearance of all lesions, PR is defined as at least a 30% decrease in the sum of the LD of lesions, taking as reference the baseline sum LD. PD is defined as at least a 20% increase in the sum of the LD of lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
  • Progression Free Survival (PFS) [ Time Frame: From randomization until disease progression or death whichever occurs first (up to 1 year) ]
    PFS is defined as time from start of study treatment to first documentation of disease progression. Per RECIST V1.1, PD is defined as at least a 20% increase in the sum of the LD of lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
  • Overall Survival (OS) [ Time Frame: Baseline up to 1 year ]
    OS is the time from start of study treatment to date of death due to any cause.
  • Percentage of Participants with TEAEs in the Tumor-Specific Cohorts [ Time Frame: Baseline up to 1 year ]
    Percentage of participants with Grade ≥3 TEAEs, SAEs, TEAEs leading to treatment discontinuation or dose modifications, and clinically significant changes in laboratory values and vital sign measurements in the tumor-specific cohorts will be reported. An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. A SAE is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors
Official Title  ICMJE An Open-Label, Phase 2, Parallel Arm Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 Single Agent in Patients With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors
Brief Summary The purpose of this study is to confirm the safety and tolerability of TAK-931 in a cohort of Western participants with metastatic solid tumors and to evaluate the anti-tumor activity of TAK-931 in participants with metastatic pancreatic cancer, colorectal cancer (CRC), squamous esophageal cancer (sqEC), and squamous non-small-cell lung cancer (sqNSCLC).
Detailed Description

The drug being tested in this study is called TAK-931. TAK-931 blocks function of a specific protein called CDC7 kinase in the human body. TAK-931 is being tested in participants with metastatic cancer (colorectal, pancreatic, sqNSCLC and sqEC) in the United States and Japan and also in the participants with any type of metastatic cancer with no standard therapeutic alternative in the United States only. This study will look at the safety, tolerability and pharmacokinetics of TAK-931.

The study will enroll approximately 160 participants. Participants will be enrolled in 5 cohorts: 1) Western safety cohort, to be enrolled in the United States only, will include non-Japanese participants with metastatic solid tumors and no standard therapeutic alternative, 2) Metastatic pancreatic cancer cohort, 3) Metastatic colorectal cancer cohort, 4) Metastatic sqNSCLC cohort, and 5) Metastatic sqEC cohort. All participants will receive:

• TAK-931 50 mg capsules

All participants will be asked to take one 50 mg capsule at the same time of the day every day for 14 days, followed by 7 days break in 21-day cycles throughout the study.

This multi-center trial will be conducted in the United States and Japan. The overall time to participate in this study is approximately 24 months. Participants will make multiple visits to the clinic. Participants in both Western cohort and disease specific cohorts will be followed for progression-free survival every 12 weeks after the last dose of the study drug until the occurrence of disease progression, loss to follow up, consent withdrawal, death, start of subsequent antineoplastic therapy, study termination, or until 6 months after discontinuation of the study treatment, whichever occurs first. Once disease progression is confirmed, participants in the disease-specific cohorts will be followed for overall survival every 12 weeks until death, loss to follow up, consent withdrawal, study termination, or transfer of a participant to a long term safety study, single participant investigational new drug application, or similar program after the last dose of the study drug.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Metastatic Pancreatic Cancer
  • Colorectal Cancer
  • Esophageal Neoplasms
  • Carcinoma, Non-small-cell Lung
Intervention  ICMJE Drug: TAK-931
50 mg capsules
Study Arms  ICMJE Experimental: TAK-931
TAK-931 50 milligram (mg), capsules, orally, once daily for 14 days, followed by 7-day washout period, in 21-day cycles until disease progression or unacceptable treatment-related toxicity (Up to 1 year).
Intervention: Drug: TAK-931
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: July 17, 2018)
160
Original Estimated Enrollment  ICMJE
 (submitted: August 23, 2017)
88
Estimated Study Completion Date  ICMJE August 26, 2020
Estimated Primary Completion Date November 19, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Adult male or female participants aged >=20 years (Japan) or >=18 years (United States).
  2. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
  3. Has pathologically confirmed metastatic pancreatic adenocarcinoma that has progressed after, at least, a first line of standard systemic chemotherapy for the metastatic disease, OR participants with pathologically confirmed metastatic adenocarcinoma of the colon or rectum who have progressed to at least 2 lines of standard systemic chemotherapy for the metastatic disease, OR participants with pathologically confirmed locally advanced or metastatic sqEC that has progressed after at least a first line of standard systemic therapy for metastatic disease. First-line participants can be enrolled if a platinum doublet is contraindicated or refused by the participants, OR pathologically confirmed locally advanced or metastatic sqNSCLC that has progressed after at least 2 lines of standard systemic therapy for metastatic disease.
  4. For the Western safety cohort only: participants with locally advanced or metastatic solid tumor for whom no standard treatment with an established survival benefit is available or if the participant refuses other standard therapy.
  5. For disease-specific cohort participants: measurable disease per RECIST v. 1.1
  6. Left ventricular ejection fraction greater than (>) 50% as measured by ECHO or MUGA scan within 4 weeks before receiving the first dose of study drug.
  7. Recovered to Grade 1 or baseline from all toxic effects of previous therapy (except alopecia or neuropathy).
  8. Suitable venous access for the study-required blood sampling.
  9. For the Western safety cohort only: willingness to undergo serial skin tissue biopsies.
  10. For disease-specific cohort participants: Must have an archival (banked) tumor sample or agree to have a new (fresh) tumor biopsy during the screening period. If a new tumor sample is needed, the disease should be accessible for a nonsignificant risk biopsy procedure (those occurring outside the brain, lung/mediastinum, and pancreas, or obtained with endoscopic procedures not extending beyond the stomach or bowel). For participants in the Western safety cohort, this biopsy is optional.

Exclusion Criteria:

  1. Participants who require continuous use of proton pump inhibitors (PPIs) or histamine-2 (H2) receptor antagonists and participants who are taking PPIs within 5 days before the first dose of study drug.
  2. Treatment with clinically significant enzyme inducers, such as phenytoin, carbamazepine, phenobarbital, rifampin, rifabutin, rifapentine, or Saint John's wort within 14 days before the first dose of study drug.
  3. Treatment with any systemic anticancer treatment (including investigational products) within 30 days or 5 half-lives, whichever is shorter, before the first dose of study drug.
  4. History of any of the following within the last 3 months before administration of the first dose of study drug:

    • Ischemic myocardial event including angina requiring therapy and artery revascularization procedures, myocardial infarction, and unstable symptomatic ischemic heart disease.
    • Ischemic cerebrovascular event, including transient ischemic attack and artery, revascularization procedures.
    • Significant, uncontrolled cardiac arrhythmia (including atrial flutter/fibrillation, ventricular fibrillation, or ventricular tachycardia).
    • New York Heart Association Class III to IV heart failure.
    • Any other cardiac condition that, in the opinion of the investigator, could pose an additional risk for participation in the study (example, pericardial effusion or restrictive cardiomyopathy).
    • Baseline prolongation of the QT interval corrected for heart reate (HR) using Fridericia's formula (QT interval corrected for heart rate using Fridericia's formula (QTcF); example, repeated demonstration of QTcF interval >480 millisecond (ms), history of congenital long QT syndrome, or torsades de pointes).
  5. Hypertension that is unstable or not controlled by medication.
  6. History of uncontrolled brain metastasis unless:

    • Previously treated with surgery, whole-brain radiation, or stereotactic radiosurgery, and
    • Stable disease (SD) for >=30 days, without steroid use (or stable steroid dose established for >=14 days before the first dose of TAK-931).
  7. Known history of human immunodeficiency virus infection.
  8. Known hepatitis B virus (HBV) surface antigen seropositive or detectable hepatitis C virus (HCV) infection viral load. Note: Participants who have positive HBV core antibody or HBV surface antigen antibody can be enrolled but must have an undetectable HBV viral load.
  9. Prior treatment with radiation therapy involving >=25% of the hematopoietically active bone marrow within 3 months before the first dose of study drug.
  10. Participants with known microsatellite instability-high (MSI-H) genotype or known wild type tumor protein 53 (TP53) per local testing.
  11. Western Safety Cohort Only: Participants with Japanese heredity.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Takeda Study Registration Call Center +1-866-835-2223 globaloncologymedinfo@takeda.com
Listed Location Countries  ICMJE United States,   Japan
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03261947
Other Study ID Numbers  ICMJE TAK-931-2001
U1111-1192-7975 ( Registry Identifier: World Health Organization )
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Yes
Plan Description: Takeda makes patient-level, de-identified data sets and associated documents available after applicable marketing approvals and commercial availability have been received, an opportunity for the primary publication of the research has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com/Approach for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.
Responsible Party Takeda ( Millennium Pharmaceuticals, Inc. )
Study Sponsor  ICMJE Millennium Pharmaceuticals, Inc.
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Medical Monitor Takeda
PRS Account Takeda
Verification Date September 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP